Terns Pharmaceuticals was a clinical-stage oncology company whose TERN news centered on TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia. Company updates covered clinical and regulatory disclosures for TERN-701, licensing arrangements tied to the program, operating and financial results, equity compensation actions, and shareholder or capital-structure matters.
In May 2026, Merck completed its acquisition of Terns, and Terns became a wholly owned subsidiary of Merck. The company’s common stock was removed from Nasdaq trading, making TERN a historical public-company ticker tied to the oncology program and the completed corporate-status change.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.